New HSP27 inhibitors efficiently suppress drug resistance development in cancer cells
Metrics: PDF 1805 views | HTML 2392 views | ?
Jörg C. Heinrich1,*, Sainitin Donakonda1,*, V. Joachim Haupt1,*, Petra Lennig2, Yixin Zhang2, Michael Schroeder1
1Biotechnology Center, Technische Universität Dresden, 01307 Dresden, Germany
2B CUBE – Center for Molecular Bioengineering, Technische Universität Dresden, 01307 Dresden, Germany
*These authors contributed equally to this work
Michael Schroeder, email: firstname.lastname@example.org
Keywords: drug repositioning, drug repurposing, HSPB1, BVDU, binding site
Received: June 29, 2016 Accepted: August 26, 2016 Published: September 08, 2016
Drug resistance is an important open problem in cancer treatment. In recent years, the heat shock protein HSP27 (HSPB1) was identified as a key player driving resistance development. HSP27 is overexpressed in many cancer types and influences cellular processes such as apoptosis, DNA repair, recombination, and formation of metastases. As a result cancer cells are able to suppress apoptosis and develop resistance to cytostatic drugs. To identify HSP27 inhibitors we follow a novel computational drug repositioning approach. We exploit a similarity between a predicted HSP27 binding site to a viral thymidine kinase to generate lead inhibitors for HSP27. Six of these leads were verified experimentally. They bind HSP27 and down-regulate its chaperone activity. Most importantly, all six compounds inhibit development of drug resistance in cellular assays. One of the leads – chlorpromazine – is an antipsychotic, which has a positive effect on survival time in human breast cancer. In summary, we make two important contributions: First, we put forward six novel leads, which inhibit HSP27 and tackle drug resistance. Second, we demonstrate the power of computational drug repositioning.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.